Tevogen Ties CEO's 8M Share Grant to $1B Revenue Milestone
TVGN has more than doubled off its 52-week low of $3.636 on light trading volume (0.2× avg).
Summary
Tevogen granted CEO Ryan Saadi 8 million restricted shares and CFO Kirti Desai 750,000 restricted shares, vesting only upon reaching $1 billion in revenue by September 2031. The grants give Saadi 74.4% voting control.
Key Events · Executive and Board Changes · TVGN
-
CEO and CFO Receive Performance-Based Restricted Stock
On September 14, 2026, CEO Ryan Saadi received 8,000,000 restricted shares and CFO Kirti Desai received 750,000 restricted shares under the 2024 Omnibus Incentive Plan.
-
Vesting Requires $1B Revenue by 2031
All restricted shares vest only upon Board certification of $1.0 billion in aggregate revenue by September 30, 2031 — a threshold far above current operations given the $11.2M Q2 net loss and $1.1M cash balance.
-
Voting Control Concentrates with CEO
Immediately after the grant, Saadi directly or indirectly owns 74.4% and Desai owns 6.3% of the 15,736,540 outstanding shares, with full voting rights on unvested restricted shares.
-
Forfeiture and Clawback Provisions
Restricted shares are subject to forfeiture on termination, failure to meet the revenue threshold, change in control without assumption, or conduct detrimental to the company, including a 12-month clawback on vested shares.
Analysis · TVGN · Life Sciences
On September 14, 2026, Tevogen granted CEO Ryan Saadi 8 million restricted shares and CFO Kirti Desai 750,000 restricted shares. The awards vest only if the company achieves $1 billion in aggregate revenue by September 30, 2031 — a threshold roughly 200x the company's current revenue base given its $11.2M quarterly net loss and $1.1M cash position. Until vesting, the grants are non-dilutive to current shareholders, but they carry immediate voting rights, pushing Saadi's ownership to 74.4% and Desai's to 6.3% of the 15.7 million shares outstanding. This follows the August 2026 shareholder approval to add 100 million shares to the equity plan, signaling aggressive equity-based retention for a company with minimal cash runway.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TVGN was trading at $7.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $3.64 to $43.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.